Killing of gram-negative bacteria with normal human serum and normal bovine serum: Use Of lysozyme and complement proteins in the death Of Salmonella strains O48

Microbial Ecology

Volumn 58, Issue 2, 2009, Pages 276-289

  Bugla Ploskonska G ^a   Kiersnowski, A ^b   Futoma Koloch B ^a   Doroszkiewicz, W ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); BOVINAE; NEGIBACTERIA; SALMONELLA; VERTEBRATA;

BENTONITE; CALCIUM; COMPLEMENT; LYSOZYME;

ADSORPTION; ANIMAL; ARTICLE; CATTLE; CHEMISTRY; COMPLEMENT ACTIVATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; METABOLISM; SALMONELLA; SERUM; SERUM BACTERICIDAL ACTIVITY; X RAY DIFFRACTION;

ADSORPTION; ANIMALS; BENTONITE; BLOOD BACTERICIDAL ACTIVITY; CALCIUM; CATTLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; MURAMIDASE; SALMONELLA; SERUM; X-RAY DIFFRACTION;

EID: 68549104133     PISSN: 00953628     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00248-009-9503-2     Document Type: Article

References (61)

1. Aramini JM, Drakenberg T, Hiraoki T, Ke Y, Nitta K, Vogel HJ (1992) Calcium-43 NMR studies of calcium binding-lysozymes and alpha-lactalbumins. Biochemistry 31:6761-6768.
2. Arora DK, Ajello L, Mukerji KG (1991) Handbook of applied mycology. Humans, animals, and insects. Vol. 2. CRC, Boca Raton.
3. Asuri P, Karajanagi SS, Kane RS, Dordick JS (2007) Polymer-nanotube-enzyme composites as active antifouling films. Small 1:50-53.
4. Bera A, Biswas R, Herbert S, Götz F (2006) The presence of peptydoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity. Infect Immun 8:4598-4604.
5. Bernet J, Mullich J, Singh AK, Sahu A (2003) Viral mimicry of the complement system. J Biosci 3:249-264.
6. Bloch EF, Schmetz MA, Foulds J, Hammer CH, Frank MM, Joiner KA (1987) Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing. J Immunol 138(3):842-848.
7. Blom AM, Villoutreix BO, Dahlback B (2004) Functions of human complement inhibitor C4b-binding protein in relation to its structure. Arch Immunol Ther Exp 2:83-95.
8. Bugla-Płoskońska G, Doroszkiewicz W (2006) Bactericidal activity of normal bovine serum (NSB) directed against some Enterobacteriaceae with sialic acid-containing lipopolysaccharides (LPS) as a component of cell wall. Pol J Microbiol 55:169-174.
9. Bugla-Płoskońska G, Korzeniowska-Kowal A, Gamian A, Doroszkiewicz W (2004) Bactericidal activity of serum against Salmonella O48 serovars. European Congress of Chemotherapy Infection. 24th Reunion Interdiscipilinaire de Chimiotherapie Anti-Infectieuse. Paris 2004. Int J Antimicrob Agents 24:203.
10. Czuprynski CJ, Balish E (1981) Killing of Listeria monocytogenes by conventional and germfree rat sera. Infect Immun 2:348-354.
11. Donaldson DM, Roberts RR, Larsen RH, Tew JG (1974) Interrelationship between serum beta-lysin, lysozyme, and the antibody-complement system in killing Escherichia coli. Infect Immun 3:657-666.
12. Donaldson DM, Tew JG (1977) Beta-lysin of platelet origin. Bacteriol Rev 2:501-513.
13. Doroszkiewicz W (1997) Mechanism of antigenic variation in Shigella flexneri bacilli. IV. Role lipopolysaccharides and their components in the sensitivity of Shigella flexneri 1b and its Lac+ recombinant to killing action of serum. Arch Immunol Ther Exp 45:235-242.
14. Dumestre-Pérard C, Doerr E, Colomb MG, Loos M (2007) Involvement of complement pathways in patients with bacterial septicemia. Mol Immunol 7:1631-1638.
15. Düring K, Porsch P, Mahn A, Brinkmann O, Gieffers W (1999) The non-enzymatic microbicidal activity of lysozymes. FEBS Lett 449:93-100.
16. Edinger D, Bello E, Mates A (1977) The heterocytotoxicity of human serum. I. Activation of the alternative complement pathway by heterologous target cells. Cell Immunol 29:174-186.
17. Facon MJ, Skura BJ (1996) Antibacterial activity of lactoferricin, lysozyme and EDTA against Salmonella enteritidis. Int Dairy J 3:303-313.
18. Farkas A, Dekany I (2001) Interlamellar adsorption of organic pollutants in hydrophobic montmorillonite. Colloid Polym Sci 279:459-467.
19. Feingold DS, Goldman JH, Kuritz HM (1968) Locus of the action of serum and the role of lysozyme in the serum bactericidal reaction. J Bacteriol 6:2118-2126.
20. Fine DP, Marney SR, Colley DG, Sergent JS, Des Prez R (1972) C3 shunt activation in human serum chelated with EGTA. J Immunol 109:807-809.
21. Futoma B, Bugla-Płoskońska G, Doroszkiewicz W (2005) Bactericidal complement activity against Salmonella enterica strains. Pol J Environ Stud 14:101-104.
22. Gamian A, Ch Jones, Lipiński T, Korzeniowska-Kowal A, Ravenscroft N (2000) Structure of the sialic acid-containing O-specific polysaccharide from Salmonella enterica serovar Toucra O48 lipopolysaccharide. Eur J Biochem 267:3160-3166.
23. 35:- in Southern Italy: molecular characterisation of human, animal and environmental isolates. J Clin Microbiol 9:3502-3505.
24. Grimond PD, Weill FX (2007) Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for Reference and Research on Salmonella. 9th ed.
25. Harmat V, Gál P, Kardos J, Szilágyi K, Ambrus G, Végh B, Náray-Szabó G, Závodszky P (2004) The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interaction. J Mol Biol 5:1533-1546.
26. Harris JB, Baresch-Bernal A, Rollins SM, Alam A et al (2006) Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar Typhi. Infect Immun 74:5161-5168.
27. Hill AW, Shears AL, Hibbitt KG (1976) Increased antibacterial activity against Escherichia coli in bovine serum after the induction of endotoxin tolerance. Infect Immun 1:257-265.
28. Holland MCH, Lambris JD (2005) Complement: encyclopedia of life sciences. Wiley, UK.
29. Hule RA, Pochan DJ (2007) Poly (L-Lysine) and clay nanocomposite with desired matrix secondary structure. Effects of polypeptide molecular weight. J Polym Sci B Polym Phys 45:239-252.
30. Kiersnowski A, Da{ogonek}browski P, Budde H, Kressler J, Pigłowski J (2004) Synthesis and structure of poly(epsilon-caprolactone)/synthetic clay nano-intercalates. Eur Polym J 40:2591-2598.
31. Kiersnowski A, Serwadczak M, Futoma-Kołoch B, Bugla-Płoskońska G, Kwiatkowski R, Doroszkiewicz W, Pigłowski J (2009) Delamination of montmorillonite in serum-a new approach to obtaining clay-based biofunctional hybrid materials. Appl Clay Sci (in press).
32. Komarneni S, Kozai N, Paulus WJ (2001) Superselective clay for radium uptake. Nature 410:771.
33. Kroll HP, Bhakdi S, Taylor PW (1983) Membrane changes induced by exposure of Escherichia coli to human serum. Infect Immun 3:1055-1066.
34. Laible NJ, Germaine GR (1985) Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against Streptococcus sanguis and Streptococcus faecalis: inhibition by chitin oligosaccharides. Infect Immun 3:720-728.
35. Li K, Sacks SH, Zhou W (2007) The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol Immunol 44:3866-3874.
36. Luckarift HR, Dickreson MB, Sandhage KH, Spain JC (2006) Rapid room-temperature synthesis of antibacterial bionanocomposites of lysozyme with amorphous silica or titiania. Small 5:640-643.
37. Lutz HU, Fumia S, Schurtenberger C, Alaia V (2007) Opinion paper: stimulation of complement amplification or activation of the alternative pathway of complement? Mol Immunol 16:3862-3865.
38. Lyatskaya Y, Balazs AC (1998) Modeling the phase behavior of polymer clay composites. Macromolecules 19:6676-6668.
39. Martinez RJ, Carroll SF (1980) Sequential metabolic expressions of the lethal process in human serum treated Escherichia coli: role of lysozyme. Infect Immun 28:735-745.
40. Mielnik G, Gamian A, Doroszkiewicz W (2001) Bactericidal activity of normal cord serum (NCS) against Gram-negative rods with sialic acid-containing lipopolysaccharides (LPS). FEMS Immunol Med Microbiol 31:169-173.
41. Mokracka-Latajka G, Jankowski J, Grzybek-Hryncewicz K, Krzyżanowska B (1996) The mechanism of bactericidal cation of normal human serum against Salmonella rods. Acta Microbiol Pol 2:169-180.
42. Morgan BP (1999) Regulation of the complement membrane attack pathway. Crit Rev Immunol 3:173-198.
43. Odumeru JA, Wiseman GM, Ronald AR (1985) Role of lipopolysaccharide and complement in susceptibility of Haemophilus ducrei to human serum. Infect Immun 50:495-499.
44. Ogundele MO (1998) A novel anti-inflammatory activity of lysozyme: modulation of serum complement activation. Med Inflamm 7:363-365.
45. Prescott LM, Harley JP, Klein DA (2002) Microbiology, 5th edn. McGraw-Hill, Boston.
46. Rautemaa R, Meri S (1999) Complement-resistance mechanisms of bacteria. Microb Infect 1:785-794.
47. Schiller NL, Alazard MJ, Borowski RS (1984) Serum sensitivity of a Pseudomonas aeruginosa mucoid strains. Infect Immun 45:748-755.
48. Schmidt BZ, Colten HR (2000) Complement: a critical test of its biological importance. Immunol Rev 178:166-176.
49. Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjöholm AG, Wurzner R, Loos M, Tedesco F, Sim RB, Garred P, Alexopoulos E, Turner MW, Daha MR (2005) Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Meth 1-2:187-198.
50. Sixtrude L, Peacor DR (2002) First-principles study of illite-smectite and implications for clay mineral systems. Nature 420:165-167.
51. Sotirov L, Smerdjiev V, Maslev T, Gerchev G (2006) Breed and age-related differences in lysozyme concentration and complement activity in rams. Trakia J Sc 3:20-24.
52. Steinrauf LK, Shiuan D, Yang WJ, Chiang MY (1999) Lysozyme association with nucleic acids. Biochem Biophys Res Commun 2:366-370.
53. Stribeck N (2007) X-ray scattering of soft matter. Springer, UK.
54. Taylor PW (1992) Complement-mediated killing of susceptible gram-negative bacteria: an elusive mechanism. Exp Clin Immunogenet 9:48-56.
55. Traub WH, Fukshima PI (1978) Neutralization of human serum lysozyme by sodium polyanethol sulfonate but not by sodium amylosulfate. J Clin Microbiol 3:306-312.
56. Virella G (1997) Microbiology and infectious diseases, 3rd edn. Williams & Wilkins, UK.
57. Wang Y, Bjes ES, Esser AF (2000) Molecular aspects of complement-mediated bacterial killing. Periplasmic conversion of C9 from a protoxin to a toxin. J Biol Chem 7:4687-4692.
58. Wedgwood RJP, Janeway CA (1953) Serum complement in children with "collagen diseases". Pediatrics 11:569-581.
59. Woodward DL, Khakhria R, Johnson WM (1997) Human salmonellosis associated with exotic pest. J Clin Microbiol 11:2786-2790.
60. Würzner R (1999) Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 4-5:249-260.
61. Zipfel PF, Würzner R, Skerka C (2007) Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol Immunol 16:3850-3857.